MX2022007436A - Inhibidores de la autotaxina y sus usos. - Google Patents
Inhibidores de la autotaxina y sus usos.Info
- Publication number
- MX2022007436A MX2022007436A MX2022007436A MX2022007436A MX2022007436A MX 2022007436 A MX2022007436 A MX 2022007436A MX 2022007436 A MX2022007436 A MX 2022007436A MX 2022007436 A MX2022007436 A MX 2022007436A MX 2022007436 A MX2022007436 A MX 2022007436A
- Authority
- MX
- Mexico
- Prior art keywords
- autotaxin inhibitors
- autotaxin
- methods
- compositions
- inhibitors
- Prior art date
Links
- 102100021977 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Human genes 0.000 title abstract 2
- 108050004000 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229940122849 Autotaxin inhibitor Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Nutrition Science (AREA)
Abstract
Aquí se describen métodos y composiciones para el tratamiento de afecciones, enfermedades o trastornos asociados con la actividad de la autotaxina. Los métodos y composiciones descritos en este documento incluyen el uso de al menos un compuesto inhibidor de autotaxina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562167216P | 2015-05-27 | 2015-05-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022007436A true MX2022007436A (es) | 2022-07-19 |
Family
ID=57393709
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017015225A MX2017015225A (es) | 2015-05-27 | 2016-05-24 | Inhibidores de la autotaxina y sus usos. |
MX2022007436A MX2022007436A (es) | 2015-05-27 | 2017-11-27 | Inhibidores de la autotaxina y sus usos. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017015225A MX2017015225A (es) | 2015-05-27 | 2016-05-24 | Inhibidores de la autotaxina y sus usos. |
Country Status (15)
Country | Link |
---|---|
US (2) | US10632104B2 (es) |
EP (2) | EP3302490B1 (es) |
JP (2) | JP6873919B2 (es) |
KR (2) | KR20240060887A (es) |
CN (2) | CN107921048A (es) |
AU (3) | AU2016268250B2 (es) |
BR (1) | BR122023011445B1 (es) |
CA (1) | CA2986759A1 (es) |
EA (2) | EA036337B1 (es) |
ES (1) | ES2915267T3 (es) |
HK (1) | HK1253587A1 (es) |
IL (2) | IL280863B1 (es) |
MX (2) | MX2017015225A (es) |
SG (1) | SG10201911204WA (es) |
WO (1) | WO2016191427A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI3071561T1 (sl) | 2013-11-22 | 2021-11-30 | Sabre Therapeutics Llc | Spojine, ki inhibirajo avtotaksin |
US10632104B2 (en) | 2015-05-27 | 2020-04-28 | Sabre Therapeutics Llc | Autotaxin inhibitors and uses thereof |
CN107021915A (zh) * | 2017-04-27 | 2017-08-08 | 李亚庆 | 一种治疗妇科炎症的化合物及制备方法和应用 |
CA3072346A1 (en) * | 2017-08-14 | 2019-02-21 | Camp4 Therapeutics Corporation | Methods of treating liver diseases |
WO2019172651A1 (ko) | 2018-03-06 | 2019-09-12 | 주식회사 엘지화학 | 편광판 및 이를 포함하는 화상 표시 장치 |
WO2020061114A1 (en) * | 2018-09-18 | 2020-03-26 | Metacrine, Inc. | Farnesoid x receptor agonists for the treatment of disease |
CN112190708B (zh) * | 2019-07-08 | 2023-09-05 | 上海交通大学医学院附属瑞金医院 | 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用 |
CN114767863B (zh) * | 2022-04-29 | 2024-01-30 | 西北工业大学 | 一种enpp2基因或蛋白在调控结直肠癌细胞中的应用 |
WO2023215196A1 (en) * | 2022-05-03 | 2023-11-09 | Sabre Therapeutics Llc | Polymorphic and salt forms of the autotaxin inhibitor cudetaxestat |
WO2023215684A1 (en) * | 2022-05-05 | 2023-11-09 | The Trustees Of Indiana University | Therapeutic strategies to manage facial contractures post injury |
CN116239577A (zh) * | 2023-03-27 | 2023-06-09 | 沈阳药科大学 | 一种制备Cudetaxestat的方法 |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5210574A (en) | 1991-03-08 | 1993-05-11 | Mita Industrial Co., Ltd. | Photosensitive drum body-mounting mechanism including a drive coupling member with a coupling protrusion adapted to bite into the inner surface of the mechanism's photosensitive drum |
US5186522A (en) | 1991-09-24 | 1993-02-16 | Midland Brake, Inc. | Air dryer purge line |
WO1994011661A1 (en) | 1992-11-10 | 1994-05-26 | Caterpillar Inc. | Solenoid valve assembly |
US5407368A (en) | 1992-12-15 | 1995-04-18 | Minnesota Mining And Manufacturing Company | Electrode connector |
US5761473A (en) | 1993-01-08 | 1998-06-02 | International Business Machines Corporation | Method and system for increased instruction synchronization efficiency in a superscalar processsor system utilizing partial data dependency interlocking |
US5564949A (en) | 1995-01-05 | 1996-10-15 | Thomas & Betts Corporation | Shielded compact data connector |
JP2664048B2 (ja) | 1995-03-27 | 1997-10-15 | 科学技術庁金属材料技術研究所長 | 六フッ化二ケイ素の合成法 |
GB9514473D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
WO2001030343A1 (en) | 1999-10-22 | 2001-05-03 | Merck & Co., Inc. | Pharmaceuticals for treating obesity |
US6890933B1 (en) | 2000-02-24 | 2005-05-10 | President And Fellows Of Harvard College | Kinesin inhibitors |
US6858620B2 (en) | 2000-10-03 | 2005-02-22 | Lilly Icos, Llc | Condensed pyridoindole derivatives |
AR035857A1 (es) | 2001-04-11 | 2004-07-21 | Novirio Pharmaceuticals Ltd | Fenilindoles; sus composiciones farmaceuticas y sus usos |
JP4141954B2 (ja) | 2001-09-27 | 2008-08-27 | エフ.ホフマン−ラ ロシュ アーゲー | Coxiiインヒビターとしてのインドール誘導体 |
US7528165B2 (en) | 2001-12-13 | 2009-05-05 | National Health Research Institutes | Indole compounds |
US7186746B2 (en) | 2002-08-29 | 2007-03-06 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
JP4340232B2 (ja) | 2002-08-29 | 2009-10-07 | メルク エンド カムパニー インコーポレーテッド | 抗糖尿病活性を有するインドール類 |
AU2004240649A1 (en) | 2003-05-19 | 2004-12-02 | Irm, Llc | Immunosuppressant compounds and compositions |
PT1701940E (pt) | 2003-12-23 | 2008-07-30 | Lundbeck & Co As H | Derivados de 2-(1h-indolilsulfanil)-benzil-amina como ssri |
EP1754810B1 (en) | 2004-05-19 | 2011-05-18 | Sumitomo Electric Industries, Ltd. | Method for producing group iii nitride semiconductor crystal |
KR101141650B1 (ko) | 2004-09-30 | 2012-05-17 | 엘지전자 주식회사 | 매체접속제어 계층에서의 데이터 처리 방법 및 이동통신용단말 |
WO2006041961A1 (en) | 2004-10-05 | 2006-04-20 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTHAND HUMAN SERVICES | Arylthioindole tubulin polymerization inhibitors and methods of treating or preventing cancer using same |
US20080319044A1 (en) | 2004-11-01 | 2008-12-25 | Nuada, Llc | Compounds and Methods of Use Thereof |
WO2007134169A2 (en) | 2006-05-10 | 2007-11-22 | Nuada, Llc | Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof |
US20060270634A1 (en) | 2005-05-06 | 2006-11-30 | Miller Duane D | Acetal phosphate-derived LPA mimics, PPARgamma activators, and autotaxin inhibitors |
AR054394A1 (es) | 2005-06-17 | 2007-06-20 | Lundbeck & Co As H | Derivados de 2- (1h-indolilsulfanil)-aril amina |
WO2007041600A2 (en) | 2005-10-03 | 2007-04-12 | Luminescent Technologies, Inc. | Mask-pattern determination using topology types |
US7705028B2 (en) | 2005-12-19 | 2010-04-27 | Glaxosmithkline Llc | Farnesoid X receptor agonists |
CA2690762C (en) | 2007-06-15 | 2016-06-14 | Glenn Prestwich | .alpha.-chloro and .alpha.-bromo phosphonate analogs of lysophosphatidic acid and methods of making and using thereof |
DE102007047737A1 (de) | 2007-10-05 | 2009-04-30 | Merck Patent Gmbh | Piperidin- und Piperazinderivate |
DE102007047738A1 (de) | 2007-10-05 | 2009-04-09 | Merck Patent Gmbh | Imidazolderivate |
DE102007047735A1 (de) | 2007-10-05 | 2009-04-09 | Merck Patent Gmbh | Thiazolderivate |
US8268891B1 (en) | 2007-11-13 | 2012-09-18 | University Of Memphis Research Foundation | Autotaxin inhibitors |
US8378100B2 (en) | 2008-01-09 | 2013-02-19 | University Of Virginia Patent Foundation | Phosphonate derivatives as autotaxin inhibitors |
WO2009151644A2 (en) | 2008-06-13 | 2009-12-17 | Yale University | Small molecule inhibitors of autotaxin methods of use |
US8022239B2 (en) | 2008-10-03 | 2011-09-20 | The University Of Memphis Research Foundation | Mechanism-based inactivators of autotaxin |
DE102008059578A1 (de) | 2008-11-28 | 2010-06-10 | Merck Patent Gmbh | Benzo-Naphtyridin Verbindungen |
MX2011005720A (es) | 2008-12-01 | 2011-06-17 | Merck Patent Gmbh | Pirido [4,3-d] pirimidinas 2,5-diamino sustituidas como inhibidores de autotaxina contra cancer. |
KR20120027192A (ko) | 2009-04-02 | 2012-03-21 | 메르크 파텐트 게엠베하 | 오토탁신 저해제로서의 헤테로시클릭 화합물 |
CA2757415C (en) | 2009-04-02 | 2018-02-06 | Merck Patent Gmbh | Autotaxin inhibitors |
EP2414330B1 (en) | 2009-04-02 | 2013-05-01 | Merck Patent GmbH | Piperidine and piperazine derivatives as autotaxin inhibitors |
US8445200B2 (en) * | 2009-04-15 | 2013-05-21 | The Regents Of The University Of California | Genotoxicity as a biomarker for inflammation |
EP2430455A4 (en) | 2009-05-11 | 2013-09-04 | Berg Pharma Llc | METHOD FOR THE DIAGNOSIS OF METABOLISM DISORDERS WITH EPIMETABOLIC SHIFTERS, MULTI-DIMENSIONAL INTRA CELLULAR MOLECULES OR AMBIENT INFLUENCES |
JP2010267037A (ja) | 2009-05-14 | 2010-11-25 | Fujitsu Ltd | ディスクアレイ装置 |
JP2012527444A (ja) | 2009-05-20 | 2012-11-08 | イーティーエイチ チューリッヒ | 代謝障害に関するターゲッティングマイクロrna |
US8343934B2 (en) | 2009-06-30 | 2013-01-01 | University Of Memphis | Diverse lead compound autotaxin inhibitors |
DE102009033392A1 (de) | 2009-07-16 | 2011-01-20 | Merck Patent Gmbh | Heterocyclische Verbindungen als Autotaxin-Inhibitoren II |
DE102009049211A1 (de) | 2009-10-13 | 2011-04-28 | Merck Patent Gmbh | Sulfoxide |
WO2011049433A1 (en) * | 2009-10-23 | 2011-04-28 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Diagnosis and treatment of pruritis |
US8497371B2 (en) | 2009-10-26 | 2013-07-30 | University Of Memphis Research Foundation | Pipemidic acid derivative autotaxin inhibitors |
WO2011053597A1 (en) | 2009-10-26 | 2011-05-05 | The University Of Memphis Research Foundation | Pipemidic acid derivative autotaxin inhibitors |
US9187471B2 (en) | 2010-02-19 | 2015-11-17 | Medivation Technologies, Inc. | Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use |
WO2011116867A1 (de) | 2010-03-26 | 2011-09-29 | Merck Patent Gmbh | Benzonaphthyridinamine als autotaxin-inhibitoren |
EP2558115B1 (en) | 2010-04-16 | 2019-07-31 | The Salk Institute for Biological Studies | Methods for treating metabolic disorders using fgf |
ES2646834T3 (es) | 2010-08-20 | 2017-12-18 | Amira Pharmaceuticals, Inc. | Inhibidores de autotaxina y usos de los mismos |
US8771696B2 (en) | 2010-11-23 | 2014-07-08 | Regeneron Pharmaceuticals, Inc. | Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor |
WO2012100018A1 (en) | 2011-01-20 | 2012-07-26 | University Of Tennessee Research Foundation | Inhibitors of autotaxin |
US9035056B2 (en) | 2011-02-18 | 2015-05-19 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
CN103476416B (zh) | 2011-02-18 | 2016-09-21 | 梅迪维新技术公司 | 治疗高血压的化合物和方法 |
WO2012123938A1 (en) * | 2011-03-17 | 2012-09-20 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Quinolone analogs for treating autoimmune diseases |
US9260416B2 (en) * | 2011-05-27 | 2016-02-16 | Amira Pharmaceuticals, Inc. | Heterocyclic autotaxin inhibitors and uses thereof |
GB2494154B (en) | 2011-08-31 | 2017-11-29 | Metaswitch Networks Ltd | Conditional telecommunications |
KR20130029948A (ko) | 2011-09-16 | 2013-03-26 | 현대중공업 주식회사 | 용접 캐리지 이동용 가이드레일 |
WO2013054185A1 (en) | 2011-10-13 | 2013-04-18 | Pfizer, Inc. | Pyrimidine and pyridine derivatives useful in therapy |
CN106220572B (zh) | 2011-10-28 | 2019-12-13 | 因西必泰克新有限公司 | 哒嗪衍生物的化合物、用途、组合物和试剂盒及制备方法 |
JP2013129632A (ja) | 2011-12-22 | 2013-07-04 | Ono Pharmaceut Co Ltd | Enpp2阻害化合物 |
US20130270634A1 (en) | 2012-04-12 | 2013-10-17 | Richtek Technology Corporation | High voltage device and manufacturing method thereof |
SG11201407534PA (en) | 2012-06-13 | 2014-12-30 | Hoffmann La Roche | New diazaspirocycloalkane and azaspirocycloalkane |
WO2014031170A1 (en) | 2012-08-22 | 2014-02-27 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
AU2013322838B2 (en) | 2012-09-25 | 2018-02-01 | F. Hoffmann-La Roche Ag | New bicyclic derivatives |
EA028509B1 (ru) | 2012-12-19 | 2017-11-30 | Новартис Аг | Ингибиторы аутотаксина, фармацевтические композиции и комбинации, содержащие их, и их применение в лечении заболеваний и состояний, опосредованных аутотаксином |
US9409895B2 (en) | 2012-12-19 | 2016-08-09 | Novartis Ag | Autotaxin inhibitors |
TWI499591B (zh) | 2013-01-11 | 2015-09-11 | Lilly Co Eli | 雙環嘧啶化合物 |
WO2015042052A1 (en) | 2013-09-17 | 2015-03-26 | Pharmakea, Inc. | Heterocyclic vinyl autotaxin inhibitor compounds |
EP3046905A4 (en) | 2013-09-17 | 2017-03-22 | Pharmakea Inc. | Vinyl autotaxin inhibitor compounds |
EP3049405A4 (en) * | 2013-09-26 | 2017-03-08 | Pharmakea Inc. | Autotaxin inhibitor compounds |
PE20161343A1 (es) | 2013-11-05 | 2016-12-10 | Bayer Cropscience Ag | Benzamidas sustituidas para el tratamiento de artropodos |
CL2016001118A1 (es) | 2013-11-22 | 2016-12-02 | Basf Se | Compuestos heterocíclicos de n-acilimino |
CA2930735A1 (en) | 2013-11-22 | 2015-05-28 | Pharmakea, Inc. | Tetracyclic autotaxin inhibitors |
SI3071561T1 (sl) * | 2013-11-22 | 2021-11-30 | Sabre Therapeutics Llc | Spojine, ki inhibirajo avtotaksin |
US9051320B1 (en) * | 2014-08-18 | 2015-06-09 | Pharmakea, Inc. | Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor |
US10632104B2 (en) | 2015-05-27 | 2020-04-28 | Sabre Therapeutics Llc | Autotaxin inhibitors and uses thereof |
-
2016
- 2016-05-24 US US15/574,769 patent/US10632104B2/en active Active
- 2016-05-24 EP EP16800640.1A patent/EP3302490B1/en active Active
- 2016-05-24 MX MX2017015225A patent/MX2017015225A/es unknown
- 2016-05-24 EA EA201792604A patent/EA036337B1/ru unknown
- 2016-05-24 BR BR122023011445-0A patent/BR122023011445B1/pt active IP Right Grant
- 2016-05-24 EP EP22159828.7A patent/EP4026549A1/en active Pending
- 2016-05-24 IL IL280863A patent/IL280863B1/en unknown
- 2016-05-24 JP JP2017560309A patent/JP6873919B2/ja active Active
- 2016-05-24 WO PCT/US2016/033933 patent/WO2016191427A1/en active Application Filing
- 2016-05-24 AU AU2016268250A patent/AU2016268250B2/en active Active
- 2016-05-24 CN CN201680044106.9A patent/CN107921048A/zh active Pending
- 2016-05-24 KR KR1020247014437A patent/KR20240060887A/ko active Search and Examination
- 2016-05-24 CN CN202211516732.7A patent/CN116059203A/zh active Pending
- 2016-05-24 CA CA2986759A patent/CA2986759A1/en active Pending
- 2016-05-24 KR KR1020177036376A patent/KR102663569B1/ko active IP Right Grant
- 2016-05-24 ES ES16800640T patent/ES2915267T3/es active Active
- 2016-05-24 SG SG10201911204WA patent/SG10201911204WA/en unknown
- 2016-05-24 EA EA202091731A patent/EA039684B1/ru unknown
-
2017
- 2017-11-20 IL IL255764A patent/IL255764B/en active IP Right Grant
- 2017-11-27 MX MX2022007436A patent/MX2022007436A/es unknown
-
2018
- 2018-10-08 HK HK18112793.4A patent/HK1253587A1/zh unknown
-
2020
- 2020-03-17 US US16/821,365 patent/US20200215034A1/en active Pending
- 2020-09-22 AU AU2020239656A patent/AU2020239656B2/en active Active
-
2021
- 2021-04-20 JP JP2021071253A patent/JP7274521B2/ja active Active
-
2022
- 2022-09-06 AU AU2022228098A patent/AU2022228098A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022007436A (es) | Inhibidores de la autotaxina y sus usos. | |
MX2020009780A (es) | Compuestos de inhibidor de autotaxina. | |
PH12018500899A1 (en) | Compositions and methods for inhibiting arginase activity | |
GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
MX2019003623A (es) | Composiciones y metodos para el tratamiento de afecciones oftalmicas. | |
MX2020011749A (es) | Composiciones y metodos para modular la expresion de pkk. | |
SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
MX2018006632A (es) | Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4). | |
MX2018008105A (es) | Compuestos inhibidores de metaloenzima. | |
GB2541571A (en) | Pharmaceutical compositions | |
ZA201904522B (en) | Heterocyclic inhibitors of mct4 | |
PH12017501095A1 (en) | Piperidine derivatives as hdac1/2 inhibitors | |
MX2018006700A (es) | Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4). | |
MX2017004808A (es) | Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple. | |
MX2016014436A (es) | Derivados de heterociclil-butanamida. | |
MX2019006863A (es) | Inhibidores de heparanasa y uso de los mismos. | |
MX2017014456A (es) | Usos terapeuticos de l-4-cloroquinurenina. | |
MX2017014782A (es) | Metodo para el tratamiento de enfermedad neurologica. | |
MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
MX2017004819A (es) | Metodos de tratamiento de transtornos urológicos usando sarm. | |
MX2018009662A (es) | Metodo y composicion farmaceutica para tratamiento de neurodegeneracion. | |
WO2018211324A8 (en) | Prodrugs for the treatment of disease | |
GEP201706795B (en) | Hexahydrofuropyrroles as pde1 inhibitors | |
WO2016144706A3 (en) | Autotaxin inhibitor compounds and uses thereof | |
MX2017008655A (es) | Derivados de jasmonato y composiciones de los mismos. |